Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Analysis of Gut Microbiome Profiles in Hepatocellular Carcinoma Patients Responding and Not Responding to Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis

  • By

  • Guo Lin

  • Bowei Huang

  • Shun Chen

  • Hangbin Zheng

  • Wenxin Huang

  • Juan Hu

  • Liangyi Zhou

  • Liwu Chen

  • September 9, 2026

Share

  • 1

    Beta diversity significantly differed in over 68% of studies, while alpha diversity indices showed no significant difference between responders and non-responders.

  • 2

    Actinobacteriota was enriched in responders, whereas Bacteroides was depleted in non-responders at the genus level.

  • 3

    Protective taxa correlated with lower mortality included Collinsella and Ruminococcus, while risky taxa associated with worse outcomes included Bacteroides.AF20_13LB.

  • 4

    Progression-free survival was positively correlated with taxa like Collinsella and negatively with taxa such as Prevotella 9 and Veillonella atypica.

  • 5

    Responder-associated genera were linked to beneficial metabolic pathways, while non-responder taxa were associated with detrimental metabolic processes.

Original Source(s)

Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis

  • by Guo Lin, Bowei Huang, Shun Chen, Hangbin Zheng, Wenxin Huang, Juan Hu, Liangyi Zhou, Liwu Chen

  • September 9, 2026

Related Content

Dynamic clonal evolution of multiple bypass resistance mechanisms in EGFR-mutant lung adenocarcinoma: a case report

CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis

Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up

  • September 8, 2026

  • 3 min
A pilot randomized controlled trial of a multicomponent intervention to improve sexual function in female breast cancer survivors